Zanzalintinib (XL092)

Name: Zanzalintinib (XL092) in Metastatic colorectal cancer: Current treatment options and standard of care
Published: 2026-09-14T15:39:06-04:00

Metastatic colorectal cancer

Manufacturer: Exelixis
Regulatory submission: NDA submitted December 2025
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment

Current treatment options and standard of care

23 evidence topics · 19 sources

Cytotoxic chemotherapy1 evidence topic · 2 sources
VEGF-pathway antibodies and fusion proteins2 evidence topics · 2 sources
EGFR monoclonal antibodies2 evidence topics · 2 sources
Immune checkpoint inhibitors2 evidence topics · 2 sources
VEGFR and multikinase inhibitors5 evidence topics · 4 sources
BRAF-directed combination therapy1 evidence topic · 1 source
HER2-directed therapy1 evidence topic · 1 source
KRAS G12C-directed combination therapy1 evidence topic · 1 source
NTRK inhibitors1 evidence topic · 1 source
Surgical resection1 evidence topic · 1 source
Thermal ablation1 evidence topic · 1 source
Stereotactic body radiotherapy1 evidence topic · 1 source
Intra-arterial therapies1 evidence topic · 1 source
Limitations of current therapies3 evidence topics · 7 sources